<DOC>
	<DOCNO>NCT01191814</DOCNO>
	<brief_summary>Covered self expandable metal stent ( CSEMS ) three time large diameter 10 Fr plastic stent . When compare plastic stent , randomize trial show longer patency few stent-related complication CSEMS . The investigator hypothesize placement CSEMS would better treatment option preoperative biliary decompression patient pancreatic cancer .</brief_summary>
	<brief_title>Comparison Metal Plastic Stents Preoperative Biliary Decompression</brief_title>
	<detailed_description>Covered self expandable metal stent ( CSEMS ) three time large diameter 10 Fr plastic stent . When compare plastic stent , randomize trial show longer patency few stent-related complication CSEMS . The investigator hypothesize placement CSEMS would better treatment option preoperative biliary decompression patient pancreatic cancer well drainage obstruct biliary system few adverse event .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Jaundice</mesh_term>
	<mesh_term>Jaundice , Obstructive</mesh_term>
	<criteria>Patients pancreatic cancer mass head pancreas cause jaundice . Patients 19 yrs age old Serum bilirubin &gt; 2mg/dl CT : No evidence distant metastasis local vascular invasion ( tumor surround portal mesenteric vessel 180 degree circumference irregular vessel margin ) . Karnofsky score &lt; 60 Prior ( ERCP PTC ) attempt biliary decompression indication Tumorrelated gastric outlet obstruction ( vomit oral intake &lt; 1L/day ) Ongoing plan neoadjuvant therapy Cholangitis presentation coagulopathy need reversal medication Postsurgical anatomy Multiple extrahepatic biliary stricture concomitant stricture liver hilum Failed ERCP 's ( Definition : Inability deploy biliary stent thereby require PTC surgery ) .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>obstructive jaundice</keyword>
	<keyword>Obstructive jaundice secondary pancreatic cancer</keyword>
</DOC>